What Exactly Is Value-Based Pricing? Regeneron, ICER Offer Clashing Visions
This article was originally published in The Pink Sheet Daily
Executive Summary
Regeneron CEO wants ICER to consider development risks when scoring drug value; ICER seeks intervention if price triggers 'alarm bell.'